{"count": 215, "results": [{"_id": "35966518", "pmid": 35966518, "pmcid": "PMC9363636", "title": "The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis", "journal": "Front Cardiovasc Med", "authors": ["Zhang J", "Wang X", "Tian W", "Wang T", "Jia J", "Lai R", "Wang T", "Zhang Z", "Song L", "Ju J", "Xu H"], "date": "2022-07-27T00:00:00Z", "doi": "10.3389/fcvm.2022.936817", "meta_date_publication": "2022", "meta_volume": "9", "meta_issue": "", "meta_pages": "936817", "score": 50274.504, "text_hl": "Blank 6 m PCI; diet control; @CHEMICAL_Sulfonylurea_Compounds @CHEMICAL_MESH:D013453 @@@sulfonylurea@@@ if necessary   Kwang Kon, 2004  Korea @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@CHD@@@ 63 31.49 40.6 @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ 20 mg vs. ", "citations": {"NLM": "Zhang J, Wang X, Tian W, Wang T, Jia J, Lai R, Wang T, Zhang Z, Song L, Ju J, Xu H. The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis Front Cardiovasc Med. 2022;9():936817. PMID: 35966518", "BibTeX": "@article{35966518, title={The effect of various types and doses of statins on C-reactive protein levels in patients with dyslipidemia or coronary heart disease: A systematic review and network meta-analysis}, author={Zhang J and Wang X and Tian W and Wang T and Jia J and Lai R and Wang T and Zhang Z and Song L and Ju J and Xu H}, journal={Front Cardiovasc Med}, volume={9}, pages={936817}}"}}, {"_id": "37750649", "pmid": 37750649, "title": "Effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease: a retrospective analysis.", "journal": "Eur Rev Med Pharmacol Sci", "authors": ["Li B", "Li Y", "Peng WZ", "Liu YQ", "Xu ZS", "Wen JK"], "date": "2023-09-01T00:00:00Z", "doi": "10.26355/eurrev_202309_33581", "meta_date_publication": "2023 Sep", "meta_volume": "27", "meta_issue": "17", "meta_pages": "8212-8217", "score": 50265.832, "text_hl": "Effect of @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@Ezetimibe@@@ combined with @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ in the treatment of @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@coronary heart disease@@@: a retrospective analysis.", "citations": {"NLM": "Li B, Li Y, Peng WZ, Liu YQ, Xu ZS, Wen JK. Effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease: a retrospective analysis. Eur Rev Med Pharmacol Sci. 2023 Sep;27(17):8212-8217. PMID: 37750649", "BibTeX": "@article{37750649, title={Effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart disease: a retrospective analysis.}, author={Li B and Li Y and Peng WZ and Liu YQ and Xu ZS and Wen JK}, journal={Eur Rev Med Pharmacol Sci}, volume={27}, number={17}, pages={8212-8217}}"}}, {"_id": "34836863", "pmid": 34836863, "title": "Genotoxic and cytotoxic assessment of sitagliptin and simvastatin alone and in combination.", "journal": "Pak J Pharm Sci", "authors": ["Majeed Khan H", "Nawaz H", "Aerooj H", "Sharif A"], "date": "2021-09-01T00:00:00Z", "meta_date_publication": "2021 Sep", "meta_volume": "34", "meta_issue": "5(Supplementary)", "meta_pages": "1939-1944", "score": 50262.996, "text_hl": "The findings concluded a non-genotoxic combination of @CHEMICAL_Sitagliptin_Phosphate @CHEMICAL_MESH:D000068900 @@@sitagliptin@@@ and @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ which possess a least @DISEASE_Drug_Related_Side_Effects_and_Adverse_Reactions @DISEASE_MESH:D064420 @@@cytotoxic@@@ potential suggesting the safe use of the combination both in @DISEASE_Diabetes_Mellitus_Type_2 @DISEASE_MESH:D003924 @@@T2DM@@@ and @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@CHD@@@.", "citations": {"NLM": "Majeed Khan H, Nawaz H, Aerooj H, Sharif A. Genotoxic and cytotoxic assessment of sitagliptin and simvastatin alone and in combination. Pak J Pharm Sci. 2021 Sep;34(5(Supplementary)):1939-1944. PMID: 34836863", "BibTeX": "@article{34836863, title={Genotoxic and cytotoxic assessment of sitagliptin and simvastatin alone and in combination.}, author={Majeed Khan H and Nawaz H and Aerooj H and Sharif A}, journal={Pak J Pharm Sci}, volume={34}, number={5(Supplementary)}, pages={1939-1944}}"}}, {"_id": "35482468", "pmid": 35482468, "title": "Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma.", "journal": "Ther Drug Monit", "authors": ["Vethe NT", "Husebye E", "Andersen AM", "Bergan S", "Kristiansen O", "Fagerland MW", "Munkhaugen J"], "date": "2022-08-01T00:00:00Z", "doi": "10.1097/FTD.0000000000000992", "meta_date_publication": "2022 Aug 1", "meta_volume": "44", "meta_issue": "4", "meta_pages": "558-567", "score": 50258.938, "text_hl": "We evaluated the use of pharmacokinetic measurements to monitor adherence to @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ in @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@coronary heart disease@@@ (@<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@CHD@@@). ", "citations": {"NLM": "Vethe NT, Husebye E, Andersen AM, Bergan S, Kristiansen O, Fagerland MW, Munkhaugen J. Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma. Ther Drug Monit. 2022 Aug 1;44(4):558-567. PMID: 35482468", "BibTeX": "@article{35482468, title={Monitoring Simvastatin Adherence in Patients With Coronary Heart Disease: A Proof-of-Concept Study Based on Pharmacokinetic Measurements in Blood Plasma.}, author={Vethe NT and Husebye E and Andersen AM and Bergan S and Kristiansen O and Fagerland MW and Munkhaugen J}, journal={Ther Drug Monit}, volume={44}, number={4}, pages={558-567}}"}}, {"_id": "31916523", "pmid": 31916523, "title": "Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects.", "journal": "Cardiovasc Hematol Disord Drug Targets", "authors": ["Kotlovskiy MY", "Udut EV", "Kairov GT", "Fisenko VP", "Udut VV"], "date": "2020-01-01T00:00:00Z", "doi": "10.2174/1871529X20666200109144353", "meta_date_publication": "2020", "meta_volume": "20", "meta_issue": "2", "meta_pages": "93-107", "score": 50257.234, "text_hl": "Effects of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ on the Metabolism of @CHEMICAL_Fatty_Acids @CHEMICAL_MESH:D005227 @@@Fatty Acids@@@ in Combined Secondary Prevention of @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@Coronary Heart Disease@@@: Dosage and Gender Differences between the Effects.", "citations": {"NLM": "Kotlovskiy MY, Udut EV, Kairov GT, Fisenko VP, Udut VV. Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects. Cardiovasc Hematol Disord Drug Targets. 2020;20(2):93-107. PMID: 31916523", "BibTeX": "@article{31916523, title={Effects of Simvastatin on the Metabolism of Fatty Acids in Combined Secondary Prevention of Coronary Heart Disease: Dosage and Gender Differences between the Effects.}, author={Kotlovskiy MY and Udut EV and Kairov GT and Fisenko VP and Udut VV}, journal={Cardiovasc Hematol Disord Drug Targets}, volume={20}, number={2}, pages={93-107}}"}}, {"_id": "32405982", "pmid": 32405982, "title": "Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery.", "journal": "AAPS PharmSciTech", "authors": ["Rahamathulla M", "H V G", "Veerapu G", "Hani U", "Alhamhoom Y", "Alqahtani A", "Moin A"], "date": "2020-05-13T00:00:00Z", "doi": "10.1208/s12249-020-01666-4", "meta_date_publication": "2020 May 13", "meta_volume": "21", "meta_issue": "4", "meta_pages": "129", "score": 50257.188, "text_hl": "...@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ a @CHEMICAL_Cholesterol @CHEMICAL_MESH:D002784 @@@cholesterol@@@-lowering agent used to treat @DISEASE_Hypercholesterolemia @DISEASE_MESH:D006937 @@@hypercholesterolemia@@@, @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@coronary heart disease@@@, and @DISEASE_Dyslipidemias @DISEASE_MESH:D050171 @@@dyslipidemia@@@. ", "citations": {"NLM": "Rahamathulla M, H V G, Veerapu G, Hani U, Alhamhoom Y, Alqahtani A, Moin A. Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery. AAPS PharmSciTech. 2020 May 13;21(4):129. PMID: 32405982", "BibTeX": "@article{32405982, title={Characterization, Optimization, In Vitro and In Vivo Evaluation of Simvastatin Proliposomes, as a Drug Delivery.}, author={Rahamathulla M and H V G and Veerapu G and Hani U and Alhamhoom Y and Alqahtani A and Moin A}, journal={AAPS PharmSciTech}, volume={21}, number={4}, pages={129}}"}}, {"_id": "32749629", "pmid": 32749629, "title": "Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation.", "journal": "AAPS PharmSciTech", "authors": ["El-Say KM", "Ahmed TA", "Ahmed OAA", "Elimam H"], "date": "2020-08-04T00:00:00Z", "doi": "10.1208/s12249-020-01754-5", "meta_date_publication": "2020 Aug 4", "meta_volume": "21", "meta_issue": "6", "meta_pages": "223", "score": 50248.855, "text_hl": "In contrast, the level of serum high-density lipoprotein (HDL) was significantly augmented after 4 h in @SPECIES_10116 @@@rats@@@ treated with the optimized @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SMV@@@-LSTs by 47.6%. Finally, the optimized @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@SMV@@@-LSTs showed a significant lower @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@atherosclerotic@@@ index value which could maximize its potential in decreasing the risk of @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@coronary disease@@@ and @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@atherosclerosis@@@. ", "citations": {"NLM": "El-Say KM, Ahmed TA, Ahmed OAA, Elimam H. Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation. AAPS PharmSciTech. 2020 Aug 4;21(6):223. PMID: 32749629", "BibTeX": "@article{32749629, title={Enhancing the Hypolipidemic Effect of Simvastatin in Poloxamer-Induced Hyperlipidemic Rats via Liquisolid Approach: Pharmacokinetic and Pharmacodynamic Evaluation.}, author={El-Say KM and Ahmed TA and Ahmed OAA and Elimam H}, journal={AAPS PharmSciTech}, volume={21}, number={6}, pages={223}}"}}, {"_id": "33164619", "pmid": 33164619, "pmcid": "PMC7655079", "title": "Simvastatin protects high glucose-induced H9c2 cells from injury by inducing autophagy", "journal": "Pharm Biol", "authors": ["E L", "Jiang H"], "date": "2020-12-01T00:00:00Z", "doi": "10.1080/13880209.2020.1839512", "meta_date_publication": "2020 Dec", "meta_volume": "58", "meta_issue": "1", "meta_pages": "1077-1084", "score": 50248.473, "text_hl": "... @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@Simvastatin@@@ is the first line therapeutic drug for @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@coronary heart disease@@@ and @DISEASE_Atherosclerosis @DISEASE_MESH:D050197 @@@atherosclerosis@@@. ", "citations": {"NLM": "E L, Jiang H. Simvastatin protects high glucose-induced H9c2 cells from injury by inducing autophagy Pharm Biol. 2020 Dec;58(1):1077-1084. PMID: 33164619", "BibTeX": "@article{33164619, title={Simvastatin protects high glucose-induced H9c2 cells from injury by inducing autophagy}, author={E L and Jiang H}, journal={Pharm Biol}, volume={58}, number={1}, pages={1077-1084}}"}}, {"_id": "40056690", "pmid": 40056690, "title": "Statin adherence in coronary outpatients: The relationship between a novel blood test and pharmacy registry data.", "journal": "Atherosclerosis", "authors": ["Pivoriunas J", "Engebretsen I", "Vethe NT", "Kristiansen O", "Dammen T", "Husebye E", "Fagerland MW", "Munkhaugen J", "Sverre E"], "date": "2025-02-18T00:00:00Z", "doi": "10.1016/j.atherosclerosis.2025.119138", "meta_date_publication": "2025 Feb 18", "meta_volume": "403", "meta_issue": "", "meta_pages": "119138", "score": 50231.883, "text_hl": "METHODS: In a retrospective cohort study of @SPECIES_9606 @@@patients@@@ prescribed @CHEMICAL_Atorvastatin @CHEMICAL_MESH:D000069059 @@@atorvastatin@@@ or @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ during hospitalization for a @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@coronary heart disease@@@ event, a single blood sample was collected median 18 months later. ", "citations": {"NLM": "Pivoriunas J, Engebretsen I, Vethe NT, Kristiansen O, Dammen T, Husebye E, Fagerland MW, Munkhaugen J, Sverre E. Statin adherence in coronary outpatients: The relationship between a novel blood test and pharmacy registry data. Atherosclerosis. 2025 Feb 18;403():119138. PMID: 40056690", "BibTeX": "@article{40056690, title={Statin adherence in coronary outpatients: The relationship between a novel blood test and pharmacy registry data.}, author={Pivoriunas J and Engebretsen I and Vethe NT and Kristiansen O and Dammen T and Husebye E and Fagerland MW and Munkhaugen J and Sverre E}, journal={Atherosclerosis}, volume={403}, pages={119138}}"}}, {"_id": "20492655", "pmid": 20492655, "pmcid": "PMC2887787", "title": "Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)", "journal": "Cardiovasc Diabetol", "authors": ["Bardini G", "Giorda CB", "Pontiroli AE", "Le Grazie C", "Rotella CM"], "date": "2010-05-21T00:00:00Z", "doi": "10.1186/1475-2840-9-20", "meta_date_publication": "2010 May 21", "meta_volume": "9", "meta_issue": "", "meta_pages": "20", "score": 50086.01, "text_hl": "The mean LDL-C in the ITT population was 3.28 mmol/L (126.6 mg/dL) in the EZ + simva group and 3.24 mmol/L (125.2 mg/dL) in the @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ group. Table 1 shows the types of @<m>DISEASE_Coronary_Disease</m> @DISEASE_MESH:D003327 @@@CHD@@@ reported at baseline. ", "citations": {"NLM": "Bardini G, Giorda CB, Pontiroli AE, Le Grazie C, Rotella CM. Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study) Cardiovasc Diabetol. 2010 May 21;9():20. PMID: 20492655", "BibTeX": "@article{20492655, title={Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study)}, author={Bardini G and Giorda CB and Pontiroli AE and Le Grazie C and Rotella CM}, journal={Cardiovasc Diabetol}, volume={9}, pages={20}}"}}]}